As a result of the FDA PAT initiative an increased interest in process
understanding is seen in the pharmaceutical industry. Also a rising interest in
“consistent” processes is noticed. Aim is that during pharmaceutical processing
each particle should undergo the same experience independent of equipment or
scale of operation. This paper reviews the consequences of transferring a fluid
bed process from scale 1 to a larger scale 2.